ArticleGlobal medical genetics2026
Integrating multi-omics and mendelian randomization identifies therapeutic targets for Lichen Sclerosus: A druggable genome-wide study.
Article in Global medical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lichen sclerosus (LS) is a chronic inflammatory skin disease characterized by limited treatment options and an unclear pathogenesis. This study aimed to identify potential therapeutic targets for LS by integrating druggable genome (DG) data with multi-omics and Mendelian randomization (MR). Methods: Blood expression quantitative trait loci (eQTLs) were obtained from the eQTLGen consortium, and protein quantitative trait loci (pQTLs) were sourced from the UK Biobank Pharma Proteomics Project (UKB-PPP) and the Decode cohorts. Outcome data for LS were derived from the FinnGen R12 database. We performed two-sample MR analyses to estimate the causal effects of druggable genes on LS, followed by sensitivity analyses, Steiger directionality tests, and multi-omics integration. For multi-omics integration, we cross-referenced eQTL- and pQTL-derived causal genes to identify overlapping genes supported by both transcriptomic and proteomic evidence. Functional concordance was further assessed by comparing effect directions and magnitudes between the two molecular layers. Potential drugs were predicted using the DGIdb database, and molecular docking was performed using CB-Dock2. Results: After rigorous screening and Holm-Bonferroni correction, we identified 50 druggable genes (eQTL-derived) and 35 druggable proteins (pQTL-derived) with causal effects on LS. Integrative multi-omics analysis revealed integrin subunit beta 2 (ITGB2) and poly(ADP-ribose) polymerase 1 (PARP1) as the most robust therapeutic targets. Phenome-wide association study (PheWAS) analysis indicated no significant pleiotropic effects for these genes. Protein-protein interaction and pathway enrichment analyses showed that these genes are involved in integrin-mediated cell adhesion and ADP-ribosylation processes. The DGIdb database predicted 24 potential drugs targeting ITGB2 and PARP1, and molecular docking confirmed strong binding affinities (Vina score < -5). Conclusion: This integrative MR study identifies ITGB2 and PARP1 as promising therapeutic targets for LS, providing a foundation for future drug development and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.